Zimbabwe is reaching the end game, witnessing the last, desperate throes of a regime that has destroyed one of Africa's few successful economies, plunged millions of people into grinding poverty and led to the deaths of tens of thousands from malnutrition and lack of medical care. .

GTx Reports Fourth Quarter and Year End 2006 Results

MEMPHIS, Tenn.--(BUSINESS WIRE)--Feb. 20, 2007 - GTx, Inc. (Nasdaq: GTXI), today reported financial results for the fourth quarter and year ended December 31, 2006. The net loss for the three months and year ended December 31, 2006 was $4.7 million and $35.5 million, respectively, compared with a net loss of $7.8 million and $36.8 million for the same periods in 2005. At December 31, 2006, GTx had cash and cash equivalents of $119.6 million.

"2006 was an outstanding year for GTx," said Mitchell Steiner, MD, chief executive officer of GTx. "In the first half of 2006, we obtained positive data in a Phase III ADT lipid interim analysis and attained our enrollment goal in our Phase III high grade PIN clinical trial. In the second half of 2006, GTx licensed ACAPODENE European rights to Ipsen and reported successful results from the Phase II proof of concept clinical trial of ostarine, our first-in-class SARM.

Women's Hair Loss Solution

February 23, 2007 - About 30 million American women are dealing with hair loss but very few talk about it openly. A New York City entrepreneur is trying to change that with her brazen personal style and she's bringing a styling system to Philadelphia that can transform how a woman looks.